Biomarkers and Pathogenic Mechanisms in Autoimmunity

Chan, Edward K. L.; Toubi, Elias; Conrad, Karsten

doi:10.1007/s12026-016-8864-0

Cited by 1 publication

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In part, the search for the pathogenic role of AA was fueled by observations in organ-specific autoimmune disease such as Graves disease, pernicious anemia and myasthenia gravis, which fulfilled Koch's and Witebsky's postulates adapted for autoimmunity (reviewed in Pisetsky 5 ), included passive transfer of AA into animals to replicate pathological and/or clinical features of the disease. Studies of the pathogenic role of AA in SLE have been marked by considerable progress, 6,7 with convincing examples of pathogenic autoantibodies directed against cell surface, accessible and extracellular targets such as receptors, ion channels, cytokines and complement. 6 In considering these advances, it is notable that a pathogenic role for the majority of autoantibodies directed against intracellular targets associated with SLE remains challenging although several mechanisms for disordered myeloid responses have been considered.…”

Section: Introductionmentioning

confidence: 99%

Autoantibodies in SLE: prediction and the p value matrix

Choi

Fritzler

2019

Lupus

View full text Add to dashboard Cite

Autoantibodies (AA) and antinuclear antibodies (ANA) serve as key diagnostic and classification criteria for systemic lupus erythematosus (SLE). More than 200 different AA have been reported in SLE, although only a handful (<20) are considered “mainstream” because they are widely and routinely used in diagnostic, research and clinical medicine. Although the vast majority of AA have been relegated to the diminished status of “orphan” AA, some serve as predictors of SLE because they first appear in very early or subclinical SLE. Some AA are pathogenic, whereas others are thought to protect against or ameliorate disease progression and, hence, taken together can be used as predictive biomarkers of prognosis. Although studies have shown that specific AA are detected in the preclinical phase of SLE and are biomarkers of increased risk of developing the disease, AA are currently not widely used to predict very early SLE in individuals who have low pretest probability of disease. With the advent of multianalyte arrays with analytic algorithms, emerging evidence indicates that when certain combinations of biomarkers, such as the interferon signature and stem cell factor accompany AA and ANA, the predictive power for SLE is markedly increased.

show abstract

Section: Introductionmentioning

confidence: 99%